Making sure a Clinical Trial visit can go ahead in the home can be a
complex process, and last month bad weather nearly stopped play on an
important Home Trial Support visit. Thanks to the commitment and
dedication from the entire team it went ahead against the odds.

The Challenge

The poor weather conditions meant that the Home Trial Support nurse’s flight was delayed to Springfield MO, and the dose that was delivered to the patient’s home was delayed from Florida to Dallas and then cancelled from Dallas to Springfield.

The Solution

The courier sent the dose to Arkansas and a driver drove the dose from Arkansas to Springfield; a two-hour trip during thunderstorms and poor weather warnings. The nurse managed to get to Springfield and was waiting in a local hotel for the dose to arrive. When the courier arrived at 00:30 they were able to hand the dose over to the nurse who then drove to the patient’s home with the dose, in the storm, and was able to give the dose and finish the visit at 02:30am.

What incredible teamwork by both courier and nurse to ensure that the participant received the dose and the visit did not have to be rescheduled; both parties went above and beyond the call of duty. We are very appreciative of The MRN and the nurses that conduct the visits for the trial. It is because of their service that participant burden for the trial can be minimized. - Clinical Research Development Coordinator, Washington University School of Medicine in St. Louis.

While these situations aren’t normal they do happen, and the MRN team are experienced in dealing with this and dedicated to ensuring all visits can happen safely and effectively for the patient, the nurse and the rest of the team. The nurses that we hire understand the importance of each visit and are dedicated to doing what is best for the patients at each visit.

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study. More info >>

World
Pharma Week will bring together a unique and international mix of large and
medium pharmaceutical and biotech companies, CROs, leading universities and
clinical research institutions, emerging companies and tool providers—making it
a perfect meeting-place to share experience, foster collaborations across industry
and academia, and evaluate emerging technologies.More info >>